5877-53-2

Basic information

• Product Name: 4-{[(E)-phenylmethylidene]amino}benzenesulfonamide
• Synonyms: 4-(benzylideneamino)benzene-1-sulfonamide; 4-{[(E)-Phenylmethylene]amino}benzenesulfonamide; Benzenesulfonamide, 4-[[(1E)-phenylmethylene]amino]-
• CAS NO: 5877-53-2
• Molecular Formula: C₁₃H₁₂N₂O₂S
• Molecular Weight: 260.3116
• Mol File: 5877-53-2.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 473.5°C at 760 mmHg
• Flash Point: 240.2°C
• Density: 1.25g/cm³
• Vapor Pressure: 3.91E-09mmHg at 25°C
• Refractive Index: 1.614
• CAS DataBase Reference: 4-{[(E)-phenylmethylidene]amino}benzenesulfonamide(CAS DataBase Reference)
• NIST Chemistry Reference: 4-{[(E)-phenylmethylidene]amino}benzenesulfonamide(5877-53-2)
• EPA Substance Registry System: 4-{[(E)-phenylmethylidene]amino}benzenesulfonamide(5877-53-2)

Safety Data

• Hazardous Substances Data: 5877-53-2(Hazardous Substances Data)

Upstream product

• 90-02-8 salicylaldehyde 
• 63-74-1 sulfanilamide 
• 100-52-7 benzaldehyde 

Downstream Products

• 1236219-48-9 4-(5-(6-methoxynaphthalen-2-yl)-3-oxo-1-phenylpentylamino)benzenesulfonamide 
• 1251928-05-8 4-(2-phenylimidazo[4,5-b]indol-3(4H)-yl)benzenesulfonamide 
• 104-22-3 benzylsulfamide 
• 126826-48-0 N-[1-Methyl-pyrrolidin-(2Z)-ylidene]-4-{[1-phenyl-meth-(E)-ylidene]-amino}-benzenesulfonamide 
• 538-51-2 benzylidene phenylamine 
• 121-57-3 4-aminobenzene sulfonic acid 

Relevant articles and documents

Synthesis, in vitro enzyme activity and molecular docking studies of new benzylamine-sulfonamide derivatives as selective MAO-B inhibitors

Many studies have been conducted on the selective inhibition of human monoamine oxidase B (hMAO-B) enzyme using benzylamine-sulphonamide derivatives. Using various chemical modifications on BB-4h, which was reported previously by our team and showed a significant level of MAO-B inhibition, novel benzylamine-sulphonamide derivatives were designed, synthesised, and their MAO inhibition potentials were evaluated. Among the tested derivatives, compounds 4i and 4t achieved IC50 values of 0.041 ± 0.001 μM and 0.065 ± 0.002 μM, respectively. The mechanism of hMAO-B inhibition by compounds 4i and 4t was studied using Lineweaver–Burk plot. The nature of inhibition was also determined to be non-competitive. Cytotoxicity tests were conducted and compounds 4i and 4t were found to be non-toxic. Molecular docking studies were also carried out for compound 4i, which was found as the most potent agent, within hMAO-B catalytic site.

Carbonic anhydrase inhibitors. Inhibition of human cytosolic isoforms i and II with (reduced) Schiff's bases incorporating sulfonamide, carboxylate and carboxymethyl moieties

A library of Schiff bases was synthesized by condensation of aromatic amines incorporating sulfonamide, carboxylic acid or carboxymethyl functionalities as Zn2+-binding groups, with aromatic aldehydes incorporating tert-butyl, hydroxy and/or methoxy groups. The corresponding amines were thereafter obtained by reduction of the imines. These compounds were assayed for the inhibition of two cytosolic human carbonic anhydrase (hCA, EC 4.2.1.1) isoenzymes, hCA I and II. The Ki values of the Schiff bases were in the range of 7.0-21,400 nM against hCA II and of 52-8600 nM against hCA I, respectively. The corresponding amines showed Ki values in the range of 8.6 nM-5.3 μM against hCA II, and of 18.7-251 nM against hCA I, respectively. Unlike the imines, the reduced Schiff bases are stable to hydrolysis and several low-nanomolar inhibitors were detected, most of them incorporating sulfonamide groups. Some carboxylates also showed interesting CA inhibitory properties. Such hydrosoluble derivatives may show pharmacologic applications.

Synthesis and antidiabetic performance of β-amino ketone containing nabumetone moiety

We wish to report the further design and improved synthesis that resulted in two series of target molecules, TM-1 and TM-2, with remarkably simplified structures containing β-amino ketone of discrete nabumetone moiety. These were obtained via a 'one-pot,